About Our Board

CIRM’s board—also known as the Independent Citizens’ Oversight Committee (ICOC)—is composed of up to 35 California-based patient advocates, nurses, research leaders, and biotechnology industry leaders. Visit our calendar of events to see upcoming board meetings.

Meet Our Board Members

Vito Imbasciani, PhD, MD, Chair, Independent Citizens’ Oversight Committee (ICOC)

Vito

Imbasciani, PhD, MD

Maria Gonzalez Bonneville, Vice Chair, Independent Citizens’ Oversight Committee (ICOC)

Maria

Gonzalez Bonneville

Eyad Almasri, MD

Eyad

Almasri, MD

Kim Barrett, PhD

Kim

Barrett, PhD

Dan Bernal

Dan

Bernal

George Blumenthal, PhD

George

Blumenthal, PhD

Linda Boxer, MD, PhD

Linda

Boxer, MD, PhD

John

M. Carethers, MD

Judy Chou

Judy

Chou

Le Ondra

Clark Harvey, PhD

Deborah Deas, M.D., MPH

Deborah

Deas, M.D., MPH

Anne-Marie Duliege, MD

Anne-Marie

Duliege, MD

Ysabel Duron

Ysabel

Duron

Mark Fischer Colbrie, MBA

Mark

Fischer Colbrie, MBA

Elena Flowers, PhD, RN

Elena

Flowers, PhD, RN

Judith C. Gasson, PhD

Judith

C. Gasson, PhD

David Higgins, PhD

David

Higgins, PhD

Rich Lajara

Rich

Lajara

Pat Levitt, PhD

Pat

Levitt, PhD

Hala

Madanat, PhD, MS

Linda Malkas, PhD

Linda

Malkas, PhD

Shlomo Melmed, MD

Shlomo

Melmed, MD

Carolyn Meltzer, MD

Carolyn

Meltzer, MD

Christine Miaskowski, RN, PhD, FAAN

Christine

Miaskowski, RN, PhD, FAAN

Yael

Wyte, MSW

Adriana Padilla, MD

Adriana

Padilla, MD

Joe Panetta

Joe

Panetta

Marvin Southard, DSW

Marvin

Southard, DSW

Michael J. Stamos, MD

Michae

J. Stamos, MD

Karol E. Watson, MD, PhD, FACC

Karol

E. Watson, MD, PhD, FACC

Kevin Xu

Kevin

Xu

Keith R. Yamamoto, PhD

Keith

R. Yamamoto, PhD

Meet Our Alternate Members

Monica

Carson, PhD

Harold

Collard, MD, MS

Jeffrey

Golden, MD

Joyce

Sackey, MD, FACP

Suzanne Sandmeyer, PhD

Suzanne

Sandmeyer, PhD

Donald

Taylor, PhD, MBA, CLP

Who Makes Up Our Board?

Patient advocates who keep the agency’s focus where it belongs: on the people who need treatments for chronic disease and injury. They represent a wide range of diseases including diabetes, cancer, neurodegenerative diseases, HIV/AIDS, mental health and spinal cord injury.

Nurses who provide expertise in clinical trial management or stem cell or genetic therapy delivery to inform the agency on patient care standards, quality assurance procedures and care systems

Biotechnology industry leaders who ensure that our policies and funding draw on California’s biotechnology expertise. With these board members guiding agency decisions we have confidence that the industry will be poised to work with CIRM to accelerate the process of getting these new therapies to the patients who need them.

Research leaders from nationally ranked medical schools and research institutes with track records of moving basic research to the clinic who provides the agency with scientific expertise needed to direct the agency’s funding initiatives.

How Board Members are Appointed

The University of California Chancellors at San Francisco, Davis, Los Angeles, San Diego, Irvine and Riverside can each appoint a single executive officer from their respective campus. In addition, the Chancellor at San Francisco can appoint a faculty member, physician/scientist, researcher, or executive officer from the Fresno/Clovis campus.

The Governor can appoint an executive from a California University, an executive from a nonprofit research institution, an executive from a California life sciences company, a patient advocate for spinal cord injury, a patient advocate for Alzheimer’s disease, and a patient advocate for mental health conditions.

The Lieutenant Governor can appoint an executive from a California University, an executive from a nonprofit research institution, an executive from a California life sciences company, a patient advocate for type 2 diabetes, a patient advocate for either multiple sclerosis or ALS, and a patient advocate for mental health conditions.

The Treasurer can appoint an executive from a California University, an executive from a nonprofit research institution, an executive from a California life sciences company, a patient advocate for type 1 diabetes, and a patient advocate for heart disease.

The Controller can appoint an executive from a California University, an executive from a nonprofit research institution, an executive from a California life sciences company, a patient advocate for cancer, and a patient advocate for Parkinson’s disease.

The Speaker of the Assembly can appoint a patient advocate for mental health disease or mental health conditions.

The President pro Tempore can appoint a patient advocate for HIV/AIDS.

The Governor, Lieutenant Governor, Treasurer and Controller can each nominate one person for the position of Chair and Vice-chair. The appointed members of the governing board vote from among those nominees to select those two positions.

Forms & Board Regulations

(Amended 6.27.22)

(Approved 5.24.12)

calendar icon

See our upcoming Board meetings and events

Learn more about CIRM’s Subcommittees & Taskforces icon

Learn more about our Subcommittees & Taskforces

Learn more about our Working Groups